GALAPAGOS NV(AMS:GLPG) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to GLPG. GLPG was compared to 72 industry peers in the Biotechnology industry. GLPG has an average financial health and profitability rating. GLPG is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GLPG was profitable.

In the past year GLPG has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.

In the past 5 years GLPG always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of 2.97%, GLPG belongs to the top of the industry, outperforming 80.56% of the companies in the same industry.

With an excellent Return On Equity value of 4.24%, GLPG belongs to the best of the industry, outperforming 80.56% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	2.97%
ROE	4.24%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 23.04%, GLPG belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.

GLPG's Profit Margin has improved in the last couple of years.

GLPG has a Gross Margin of 89.88%. This is amongst the best in the industry. GLPG outperforms 88.89% of its industry peers.

In the last couple of years the Gross Margin of GLPG has declined.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	23.04%
GM	89.88%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y6.72%

GM growth 3Y-3.72%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.

There is no outstanding debt for GLPG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 1.49, we must say that GLPG is in the distress zone and has some risk of bankruptcy.

With a decent Altman-Z score value of 1.49, GLPG is doing good in the industry, outperforming 62.50% of the companies in the same industry.

GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

With an excellent Debt to Equity ratio value of 0.00, GLPG belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1.49

ROIC/WACCN/A

WACC7.84%

2.3 Liquidity

A Current Ratio of 9.97 indicates that GLPG has no problem at all paying its short term obligations.

With an excellent Current ratio value of 9.97, GLPG belongs to the best of the industry, outperforming 97.22% of the companies in the same industry.

A Quick Ratio of 9.81 indicates that GLPG has no problem at all paying its short term obligations.

GLPG has a Quick ratio of 9.81. This is amongst the best in the industry. GLPG outperforms 97.22% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.97
Quick Ratio	9.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for GLPG have decreased strongly by -54.06% in the last year.

GLPG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.64% yearly.

Looking at the last year, GLPG shows a very negative growth in Revenue. The Revenue has decreased by -31.28% in the last year.

GLPG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.61% yearly.

EPS 1Y (TTM)-54.06%

EPS 3YN/A

EPS 5Y-14.64%

EPS Q2Q%-65.11%

Revenue 1Y (TTM)-31.28%

Revenue growth 3Y-16.25%

Revenue growth 5Y-18.61%

Sales Q2Q%-5.45%

3.2 Future

The Earnings Per Share is expected to decrease by -24.53% on average over the next years. This is quite bad

Based on estimates for the next years, GLPG will show a small growth in Revenue. The Revenue will grow by 4.52% on average per year.

EPS Next Y58.04%

EPS Next 2Y-6.62%

EPS Next 3Y-24.95%

EPS Next 5Y-24.53%

Revenue Next Year-6.96%

Revenue Next 2Y-3.43%

Revenue Next 3Y-5.85%

Revenue Next 5Y4.52%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.24, GLPG is valued correctly.

Based on the Price/Earnings ratio, GLPG is valued cheaply inside the industry as 93.06% of the companies are valued more expensively.

GLPG's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.35.

GLPG is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	13.24
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A cheap valuation may be justified as GLPG's earnings are expected to decrease with -24.95% in the coming years.

PEG (NY)0.23

PEG (5Y)N/A

EPS Next 2Y-6.62%

EPS Next 3Y-24.95%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GLPG does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GALAPAGOS NV

AMS:GLPG (3/7/2025, 7:00:00 PM)

24.5

-0.12 (-0.49%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-12 2025-02-12/amc

Earnings (Next)04-23 2025-04-23

Inst Owners48.62%

Inst Owner ChangeN/A

Ins Owners0.01%

Ins Owner ChangeN/A

Market Cap1.61B

Analysts50

Price Target30.84 (25.88%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)127.05%

Min Revenue beat(2)-15.5%

Max Revenue beat(2)269.59%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-7.64%

PT rev (3m)-13.78%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)59.02%

EPS NY rev (3m)-2.34%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-2.63%

Revenue NY rev (3m)-1.3%

Valuation

		Industry Rank	Sector Rank
PE	13.24
Fwd PE	N/A
P/S	3.03
P/FCF	N/A
P/OCF	N/A
P/B	0.56
P/tB	0.61
EV/EBITDA	N/A

EPS(TTM)1.85

EY7.55%

EPS(NY)-0.55

Fwd EYN/A

FCF(TTM)-6.1

FCFYN/A

OCF(TTM)-4.86

OCFYN/A

SpS8.09

BVpS43.96

TBVpS40.4

PEG (NY)0.23

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	2.97%
ROE	4.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	23.04%
GM	89.88%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y6.72%

GM growth 3Y-3.72%

GM growth 5YN/A

F-Score2

Asset Turnover0.13

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	15.4%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	9.97
Quick Ratio	9.81
Altman-Z	1.49

F-Score2

WACC7.84%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)15.33%

Cap/Sales(5y)14.79%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-54.06%

EPS 3YN/A

EPS 5Y-14.64%

EPS Q2Q%-65.11%

EPS Next Y58.04%

EPS Next 2Y-6.62%

EPS Next 3Y-24.95%

EPS Next 5Y-24.53%

Revenue 1Y (TTM)-31.28%

Revenue growth 3Y-16.25%

Revenue growth 5Y-18.61%

Sales Q2Q%-5.45%

Revenue Next Year-6.96%

Revenue Next 2Y-3.43%

Revenue Next 3Y-5.85%

Revenue Next 5Y4.52%

EBIT growth 1Y-269.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.68%

EBIT Next 3Y-17.01%

EBIT Next 5Y-15.13%

FCF growth 1Y5.43%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y21.17%

OCF growth 3YN/A

OCF growth 5YN/A

GALAPAGOS NV (GLPG.AS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens